WO1998021957A1 - Imidazoles a substitution triaryle, compositions renfermant de tels composes et modes d'utilisation - Google Patents

Imidazoles a substitution triaryle, compositions renfermant de tels composes et modes d'utilisation Download PDF

Info

Publication number
WO1998021957A1
WO1998021957A1 PCT/US1997/021019 US9721019W WO9821957A1 WO 1998021957 A1 WO1998021957 A1 WO 1998021957A1 US 9721019 W US9721019 W US 9721019W WO 9821957 A1 WO9821957 A1 WO 9821957A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
independently selected
substituted
groups independently
naphthyl
Prior art date
Application number
PCT/US1997/021019
Other languages
English (en)
Inventor
Linda L. Chang
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9702823.7A external-priority patent/GB9702823D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to CA002271963A priority Critical patent/CA2271963A1/fr
Priority to AU54427/98A priority patent/AU728760B2/en
Priority to EP97948342A priority patent/EP0948257A4/fr
Priority to JP52379798A priority patent/JP2001504490A/ja
Publication of WO1998021957A1 publication Critical patent/WO1998021957A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Les 2,4-diaryl-5-pyridylimidazoles sont des antagonistes du glucagon et des inhibiteurs de la biosynthèse et/ou de l'action du TNF-α et d'IL-1. Ces composés bloquent l'action du glucagon au niveau de son récepteur et réduisent par conséquent le taux du glucose dans le plasma. Les présents imidazoles sont également des inhibiteurs du TNF-α et de IL-1. Les composés selon l'invention peuvent être utilisés pour le traitement des maladies liées au glucagon ou à la cytokine. Les maladies liées à la cytokine correspondent à des maladies ou états dans lesquels on observe une production excessive et non régulée d'une ou plusieurs cytokines. L'interleukine-1 (IL-1) et le facteur de nécrose des tumeurs ( TNF) sont des cytokines produites par diverses cellules qui interviennent dans l'immunorégulation et dans d'autres états physiologiques tels que l'inflammation.
PCT/US1997/021019 1996-11-20 1997-11-17 Imidazoles a substitution triaryle, compositions renfermant de tels composes et modes d'utilisation WO1998021957A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002271963A CA2271963A1 (fr) 1996-11-20 1997-11-17 Imidazoles a substitution triaryle, compositions renfermant de tels composes et modes d'utilisation
AU54427/98A AU728760B2 (en) 1996-11-20 1997-11-17 Triaryl substituted imidazoles, compositions containing such compounds and methods of use
EP97948342A EP0948257A4 (fr) 1996-11-20 1997-11-17 Imidazoles a substitution triaryle, compositions renfermant de tels composes et modes d'utilisation
JP52379798A JP2001504490A (ja) 1996-11-20 1997-11-17 トリアリール置換イミダゾール、そのような化合物を含む組成物及び使用方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3146796P 1996-11-20 1996-11-20
US60/031,467 1996-11-20
GBGB9702823.7A GB9702823D0 (en) 1997-02-12 1997-02-12 Triayl substituted imidazoles, compositions containing such compounds and methods of use
GB9702823.7 1997-02-12

Publications (1)

Publication Number Publication Date
WO1998021957A1 true WO1998021957A1 (fr) 1998-05-28

Family

ID=26310972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/021019 WO1998021957A1 (fr) 1996-11-20 1997-11-17 Imidazoles a substitution triaryle, compositions renfermant de tels composes et modes d'utilisation

Country Status (5)

Country Link
EP (1) EP0948257A4 (fr)
JP (1) JP2001504490A (fr)
AU (1) AU728760B2 (fr)
CA (1) CA2271963A1 (fr)
WO (1) WO1998021957A1 (fr)

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021555A2 (fr) * 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Antagonistes des recepteurs de l'adenosine a¿3?
WO2001072737A1 (fr) * 2000-03-27 2001-10-04 Smithkline Beecham Corporation Derives de triarylimidazole utilises comme inhibiteurs de la cytokine
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6649641B2 (en) 1970-11-01 2003-11-18 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6649617B1 (en) 1998-10-07 2003-11-18 Smithkline Beecham Corporation Treatment for stroke management
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
EP1414443A1 (fr) * 2001-08-01 2004-05-06 Merck & Co., Inc. Derives de la benzimidazo 4,5-f]isoquinolinone
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
WO2004063192A1 (fr) * 2003-01-10 2004-07-29 Pharmacopeia Drug Discovery, Inc. Derives de d'imidazolyl pyrimidine utilises comme modulateurs du recepteur de il-8
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
EP1618099A2 (fr) * 2003-04-18 2006-01-25 Merck & Co., Inc. Thiazoles, oxazoles et imidazoles a substitution biaryle utilises comme bloqueurs du canal sodique
WO2006014618A2 (fr) 2004-07-22 2006-02-09 Merck & Co., Inc. Pyrazoles substitues, compositions contenant de tels composes et leurs methodes d'utilisation
EP1741446A2 (fr) 2000-01-21 2007-01-10 Novartis AG Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabetiques
WO2007033266A2 (fr) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Administration d'inhibiteurs de dipeptidyl peptidase
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
US7301036B2 (en) 2003-12-19 2007-11-27 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
WO2008004117A1 (fr) * 2006-07-06 2008-01-10 Pfizer Products Inc. Composé azolés inhibant sélectivement la pde10a
EP1992636A2 (fr) 1999-11-12 2008-11-19 Amgen Inc. Procédé pour la correction d'un mauvais repliement de bisulfure dans les molécules Fc
US7572922B2 (en) 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
EP2087908A1 (fr) 2001-06-26 2009-08-12 Amgen, Inc. Anticorps opgl
US7598285B2 (en) 2004-06-04 2009-10-06 Merck & Co., Inc Pyrazole derivatives, compositions containing such compounds and methods of use
US7598398B2 (en) 2005-10-13 2009-10-06 Merck & Co., Inc. Acyl indoles, compositions containing such compounds and methods of use
US7649009B2 (en) 2004-07-07 2010-01-19 Merck & Co., Inc. Pyrazole amide derivatives, compositions containing such compounds and methods of use
US7687534B2 (en) 2006-10-03 2010-03-30 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US7709658B2 (en) 2005-07-26 2010-05-04 Merck Sharp & Dohme Corp. Process for synthesizing a substituted pyrazole
EP2213685A1 (fr) 2002-09-06 2010-08-04 Amgen Inc. Anticorps monoclonal anti-IL-1R1 thérapeutique
US7803951B2 (en) 2005-03-30 2010-09-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
US7935713B2 (en) 2006-05-16 2011-05-03 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US7989472B2 (en) 2006-03-23 2011-08-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2011097079A1 (fr) 2010-02-03 2011-08-11 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase 1 régulant le signal d'apoptose
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
WO2013096093A1 (fr) * 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Composés en tant qu'inhibiteurs de dgat-1
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2020035482A1 (fr) 2018-08-13 2020-02-20 Iltoo Pharma Combinaison d'interleukine 2 et d'un inhibiteur de l'interleukine 1, conjugués et utilisations thérapeutiques de celle-ci
WO2023222565A1 (fr) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Procédés d'évaluation de l'épuisement de cellules souches hématopoïétiques induites par une inflammation chronique

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003097031A1 (ja) * 2002-05-22 2005-09-15 株式会社三和化学研究所 メチリデンヒドラジド化合物を有効成分とする、肥満の予防又は改善剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
IL104369A0 (en) * 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
ZA945363B (en) * 1993-07-21 1995-03-14 Smithkline Beecham Corp Novel compounds
PT797575E (pt) * 1994-12-13 2004-02-27 Hoffmann La Roche Derivados de imidazol utilizaveis como inibidores de proteina quinase em particular da tirosina quinase do egf-r

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE HCAPLUS ON STN, Chemical Abstracts Service, (Columbus, Ohio, USA), DN 120:107005, ADAMS J.L. et al., "Imidazole Derivatives and Their Use as Cytokine Inhibitors"; & WO,A,93 14081, RN's 152121-71-6, 152121-72-7, 152122-03-7, 152122-04-8, 152122-10-6, 152121-70-5, 152122-15-1 and 152121-38-5. *
DATABASE HCAPLUS ON STN, Chemical Abstracts Service, (Columbus, Ohio, USA), DN 124:86885, GALLAGHER T.F. et al., "2,4,5-Triarylimidazole Inhibitors of IL-1 Biosynthesis"; & BIOORG. MED. CHEM. LETT., 1995, Vol. 5, No. 11, RNs. 152121-38-5, 152121-71-6, 152121-72-7, pages 1171-6. *
DATABASE HCAPLUS ON STN, Chemical Abstracts Service, (Columbus, Ohio, USA), DN 125:142733, HARMON C.S. et al., "Preparation of (Diphenylimidazolyl)Pyridines as Protein Kinase Inhibitors"; & WO,A,96 18626, RN 179553-46-9. *
DATABASE HCAPLUS ON STN, Chemical Abstracts Service, (Columbus, Ohio, USA), DN 79:145754, KIKUGAWA Y. et al., "Chemistry of Diborane and Sodium Borohydride. X. Reduction of 2- or 4-Substituted Pyridines and Quinolines and 1- or 3-Substituted Isoquinolines with Sodium Borohydride"; & CHEM. PHARM. BULL., 1973, Vol. 21, No. 9, *
See also references of EP0948257A4 *

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649641B2 (en) 1970-11-01 2003-11-18 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6620825B1 (en) 1997-10-27 2003-09-16 Takeda Chemical Industries, Ltd. Adenosine A3 receptor antagonists
WO1999021555A3 (fr) * 1997-10-27 1999-07-22 Takeda Chemical Industries Ltd Antagonistes des recepteurs de l'adenosine a¿3?
WO1999021555A2 (fr) * 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Antagonistes des recepteurs de l'adenosine a¿3?
US6649617B1 (en) 1998-10-07 2003-11-18 Smithkline Beecham Corporation Treatment for stroke management
US6875760B2 (en) 1999-05-17 2005-04-05 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
EP1992636A2 (fr) 1999-11-12 2008-11-19 Amgen Inc. Procédé pour la correction d'un mauvais repliement de bisulfure dans les molécules Fc
EP1743655A1 (fr) 2000-01-21 2007-01-17 Novartis AG Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabétiques
EP1741446A2 (fr) 2000-01-21 2007-01-10 Novartis AG Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabetiques
US6906089B2 (en) 2000-03-27 2005-06-14 Smithkline Beecham Corporation Triarylimidazole derivatives as cytokine inhibitors
WO2001072737A1 (fr) * 2000-03-27 2001-10-04 Smithkline Beecham Corporation Derives de triarylimidazole utilises comme inhibiteurs de la cytokine
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6953812B2 (en) 2000-06-23 2005-10-11 Novo Nordisk, Inc. Glucagon antagonists/inverse agonists
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
EP2087908A1 (fr) 2001-06-26 2009-08-12 Amgen, Inc. Anticorps opgl
EP3492100A1 (fr) 2001-06-26 2019-06-05 Amgen Inc. Anticorps pour opgl
EP1414443A4 (fr) * 2001-08-01 2005-05-11 Merck & Co Inc Derives de la benzimidazo 4,5-f]isoquinolinone
EP1414443A1 (fr) * 2001-08-01 2004-05-06 Merck & Co., Inc. Derives de la benzimidazo 4,5-f]isoquinolinone
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
EP3020414A1 (fr) 2002-09-06 2016-05-18 Amgen, Inc Anticorps monoclonal anti-il-1r1 thérapeutique
EP2277543A1 (fr) 2002-09-06 2011-01-26 Amgen, Inc Anticorps monoclonal anti-IL-1R1 thérapeutique
EP2213685A1 (fr) 2002-09-06 2010-08-04 Amgen Inc. Anticorps monoclonal anti-IL-1R1 thérapeutique
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
WO2004063192A1 (fr) * 2003-01-10 2004-07-29 Pharmacopeia Drug Discovery, Inc. Derives de d'imidazolyl pyrimidine utilises comme modulateurs du recepteur de il-8
US7989475B2 (en) 2003-01-27 2011-08-02 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
US7572922B2 (en) 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
AU2004232936B2 (en) * 2003-04-18 2008-10-30 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
EP1618099A4 (fr) * 2003-04-18 2008-07-16 Merck & Co Inc Thiazoles, oxazoles et imidazoles a substitution biaryle utilises comme bloqueurs du canal sodique
EP1618099A2 (fr) * 2003-04-18 2006-01-25 Merck & Co., Inc. Thiazoles, oxazoles et imidazoles a substitution biaryle utilises comme bloqueurs du canal sodique
US7301036B2 (en) 2003-12-19 2007-11-27 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
US7598285B2 (en) 2004-06-04 2009-10-06 Merck & Co., Inc Pyrazole derivatives, compositions containing such compounds and methods of use
US7799818B2 (en) 2004-06-04 2010-09-21 Merck Sharp & Dohme Corp. Pyrazole derivatives, compositions containing such compounds and methods of use
US7649009B2 (en) 2004-07-07 2010-01-19 Merck & Co., Inc. Pyrazole amide derivatives, compositions containing such compounds and methods of use
EP1773330A2 (fr) * 2004-07-22 2007-04-18 Merck & Co., Inc. Pyrazoles substitues, compositions contenant de tels composes et leurs methodes d'utilisation
EP1773330A4 (fr) * 2004-07-22 2009-01-21 Merck & Co Inc Pyrazoles substitues, compositions contenant de tels composes et leurs methodes d'utilisation
WO2006014618A2 (fr) 2004-07-22 2006-02-09 Merck & Co., Inc. Pyrazoles substitues, compositions contenant de tels composes et leurs methodes d'utilisation
US7625938B2 (en) 2004-07-22 2009-12-01 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
US7803951B2 (en) 2005-03-30 2010-09-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US7709658B2 (en) 2005-07-26 2010-05-04 Merck Sharp & Dohme Corp. Process for synthesizing a substituted pyrazole
WO2007033266A2 (fr) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Administration d'inhibiteurs de dipeptidyl peptidase
US7598398B2 (en) 2005-10-13 2009-10-06 Merck & Co., Inc. Acyl indoles, compositions containing such compounds and methods of use
US7989472B2 (en) 2006-03-23 2011-08-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US7935713B2 (en) 2006-05-16 2011-05-03 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2008004117A1 (fr) * 2006-07-06 2008-01-10 Pfizer Products Inc. Composé azolés inhibant sélectivement la pde10a
US7968589B2 (en) 2006-10-03 2011-06-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US7687534B2 (en) 2006-10-03 2010-03-30 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
WO2011097079A1 (fr) 2010-02-03 2011-08-11 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase 1 régulant le signal d'apoptose
WO2013096093A1 (fr) * 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Composés en tant qu'inhibiteurs de dgat-1
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2020035482A1 (fr) 2018-08-13 2020-02-20 Iltoo Pharma Combinaison d'interleukine 2 et d'un inhibiteur de l'interleukine 1, conjugués et utilisations thérapeutiques de celle-ci
WO2023222565A1 (fr) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Procédés d'évaluation de l'épuisement de cellules souches hématopoïétiques induites par une inflammation chronique

Also Published As

Publication number Publication date
JP2001504490A (ja) 2001-04-03
EP0948257A4 (fr) 1999-12-29
AU728760B2 (en) 2001-01-18
AU5442798A (en) 1998-06-10
CA2271963A1 (fr) 1998-05-28
EP0948257A1 (fr) 1999-10-13

Similar Documents

Publication Publication Date Title
AU728760B2 (en) Triaryl substituted imidazoles, compositions containing such compounds and methods of use
AU730295B2 (en) Triaryl substituted imidazoles as glucagon antagonists
US5880139A (en) Triaryl substituted imidazoles as glucagon antagonists
AU726311B2 (en) Triaryl substituted imidazoles and methods of use
US5837719A (en) 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5776954A (en) Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
EP1109803B1 (fr) Imidazoles substitues a activite inhibitrice de la cytokine
EP0727998B1 (fr) Oxazoles pour le traitement de maladies induites par la cytokine
US5717100A (en) Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US5955480A (en) Triaryl substituted imidazoles, compositions containing such compounds and methods of use
US5792778A (en) 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
EP0859771A1 (fr) Pyrroles de pyridyle substitues, compositions contenant de tels composes et mode d'utilisation
US6350744B1 (en) Compounds having cytokine inhibitory activity
US6291457B1 (en) Compounds having cytokine inhibitory activity
MXPA99009811A (en) Substituted imidazoles useful in the treatment of inflammatory diseases
WO2001022965A1 (fr) Imizadoles substitues a activite inhibitrice de la cytokine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2271963

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1997948342

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 523797

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 54427/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1997948342

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 54427/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1997948342

Country of ref document: EP